Product information and disease descriptionPlace of product in therapyApproaches to treatment
Expected outcomes of therapy
16 evidence topics · 15 sources
OPERA-01 planned primary endpoint
“The dual primary endpoint of the overall study is blinded independent committee review (BICR)-assessed PFS, defined as the time from randomization to the date of the first documented progression or death due to any cause, in participants with ESR1-mut and ESR1-mut-nd tumors, to be assessed separately.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company statement of the OPERA-01 design objective
Observed palazestrant monotherapy outcomes and stated expected benefit (OP-1250-001)
“In an analysis of 49 patients who received palazestrant as second- or third-line therapy with or without prior chemotherapy, the median PFS was extended to 7.2 months, with a CBR of 48% overall.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Palazestrant could result in prolongation of time on endocrine therapy, thereby increasing time to disease progression and delaying the transition to cytotoxic chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Standard endocrine therapy outcomes in the EMERALD control arm
“Accordingly, 6-month PFS rates were 34.3% (95% CI, 27.2 to 41.5) versus 20.4% (95% CI, 14.1 to 26.7) for the elacestrant versus SOC arms, respectively, in all patients and 40.8% (95% CI, 30.1 to 51.4) versus 19.1% (95% CI, 10.5 to 27.8), respectively, in patients with ESR1 mutation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fulvestrant outcomes by duration of prior CDK4/6 inhibitor (EMERALD)
Standard endocrine therapy and imlunestrant outcomes in ESR1-mutated disease (EMBER-3)
Fulvestrant and vepdegestrant outcomes in ESR1-mutated disease (VERITAC-2)
“Among the 270 patients with ESR1 mutations, the median progression-free survival was 5.0 months (95% confidence interval [CI], 3.7 to 7.4) with vepdegestrant and 2.1 months (95% CI, 1.9 to 3.5) with fulvestrant (hazard ratio, 0.58 [95% CI, 0.43 to 0.78]; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Fulvestrant control arm outcomes in a PIK3CA wild-type population (VIKTORIA-1)
“The median progression-free survival was 9.3 months in the gedatolisib-triplet group, 2.0 months in the fulvestrant group (hazard ratio [HR] for progression or death, 0.24 [95% CI, 0.17 to 0.35]; P < .001), and 7.4 months in the gedatolisib-doublet group (HR, 0.33 [95% CI, 0.24 to 0.48]; P < .001 v fulvestrant).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fulvestrant control arm outcomes after an aromatase inhibitor with or without a CDK4/6 inhibitor (CAPItello-291)
“Overall, 708 patients underwent randomization; 289 patients (40.8%) had AKT pathway alterations, and 489 (69.1%) had received a CDK4/6 inhibitor previously for advanced breast cancer. In the overall population, the median progression-free survival was 7.2 months in the capivasertib–fulvestrant group, as compared with 3.6 months in the placebo–fulvestrant group (hazard ratio for progression or death, 0.60; 95% confidence interval [CI], 0.51 to 0.71; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fulvestrant with and without abemaciclib after progression on a CDK4/6 inhibitor (postMONARCH)
“At the primary analysis (258 events), the hazard ratio (HR) was 0.73 (95% CI, 0.57 to 0.95; nominal P = .017), with median PFS 6.0 (95% CI, 5.6 to 8.6) versus 5.3 (95% CI, 3.7 to 5.6) months and 6-month PFS rates of 50% and 37%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world progression-free survival with second-line therapy after first-line CDK4/6 inhibitor (systematic review)
“The most assessed outcome was median rwPFS; the weighted average median rwPFS was calculated as 3.9 months (3.3-6.0 months) for single-agent ET, 3.6 months (2.5–4.9 months) for mTORi ± ET, 3.7 months for a mix of ET and/or mTORi (3.0–4.0 months), and 6.1 months (3.7–9.7 months) for chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The real-world effectiveness of current 2 L treatments post-1 L CDK4/6i are suboptimal, highlighting an unmet need for this patient population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world progression-free survival with second-line therapy in the United States
Real-world second-line progression-free survival by treatment group in a European cohort
“Median rwPFS-2L was 5.0 months for endocrine monotherapy ( n = 27), 7.0 months for targeted therapies ( n = 65), 7.4 months for capecitabine ( n = 12), and 8.7 months for other chemotherapy agents ( n = 21).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world time to next treatment with oral SERD monotherapy in ESR1-mutated disease
“The median TTNT was 6.4 months, and the time-to-treatment-discontinuation was 4.6 months. In those with ≤1 prior lines of metastatic therapy, the TTNT was 8.8 months, compared with 6.0 months in the third-line setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote